Although some animal studies suggest that the overexpression of LCAT does not result in enhanced RCT [239,515], in clinical trials in patients with CHD, administration of the recombinant LCAT (ACP-501, another name MEDI6012) increased HDLc, favourably altered HDL metabolism, increased the apoA-I levels, CEC and raised the number of large HDL particles whilst small and intermediate-size HDL particles along with proatherogenic LDL particles decreased [516,517]. The gene discussed is APOA1; the disease is coronary artery disorder.